Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease

Investigation of Cardiac Amyloid Deposits as a Cause of Cardiac Dysfunction in Alzheimer's Disease (Untersuchung Von Kardialen Amyloidablagerungen Als Ursache Einer Funktionseinschränkung Des Herzens Bei Alzheimer Demenz)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07154394

Enrollment

Registered

2025-09-04

Start date

2022-08-15

Completion date

2025-09-14

Last updated

2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Amyloidosis, Dementia, Alzheimer Type, Mild Cognitive Impairment

Brief summary

This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart. The study will conduct additional PET/MRI scans of the heart in patients undergoing amyloid tracer PET scans for Alzheimer's evaluations. Each participant will also undergo an echocardiogram and a clinical examination of dementia. This could potentially enhance diagnostic practices in both cardiac amyloidosis and Alzheimer's disease.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients undergoing cerebral amyloid PET examination for clinical indication to clarify Alzheimer's disease * No contraindications to undergo an MRI examination * No contraindications to undergo an Amyloid PET scan

Exclusion criteria

* Patients with vascular dementia and confirmed other causes of dementia (e.g. stroke, vitamin deficiency, thyroid insufficiency, toxic causes such as alcohol) * Patients with pronounced cardiac preconditions * Pregnant and breastfeeding women

Design outcomes

Primary

Measure	Time frame
Frequency of occurrence of cardiac amyloid deposits in patients with a diagnosis of Alzheimer's disease (overall)	through study completion, an average of 1 year
Frequency of occurrence of cardiac amyloid deposits in relation to different disease manifestations (subdivided, for example, by clinical assessment of disease stage)	through study completion, an average of 1 year

Countries

Germany

Contacts

Primary ContactDavid Kersting, MD PhD

david.kersting@uk-essen.de+49-201-723-2073

Backup ContactStephan Settelmeier, MD

Outcome results